

REVIEW ARTICLE | OPEN ACCESS

Patching the scarred heart

Shuo Cong^{1-3*}, Jasper Chua^{4*}, Sauri Hernandez-Resendiz^{1,2#}

Acute myocardial infarction (AMI) and heart failure (HF) that often follows remain the leading causes of morbidity and mortality worldwide. Following MI, lost cardiomyocytes (CM) are replaced by non-contractile scar tissue that increases ventricular wall stress while diminishing myocardial performance. With the negligible regenerative capacity of the heart, the field of heart engineering and regenerative therapy for MI remains a challenge. Cardiac patch often combines the use of cells and synthetic/biomaterials with the ultimate aim of improving myocardial function. Through the years, there have been remarkable breakthroughs in the fields of stem cell and biomaterials research. The advent of human-induced pluripotent stem cells provides a potentially unlimited source of cardiomyocytes for regenerative therapy. By combining this with 3D bioprinting, it was possible to generate a cardiac patch with cell and structural organizations similar to that of the native heart. Even with vast technological advancements, the promise of the cardiac patch to treat MI has not been fulfilled. Subsequent studies revealed that exosomes, rather than the cellular component of the cardiac patch, is one of the main contributors to its cardioprotection. In this review, we present and discuss perspectives of the cardiac patch and its drawbacks and future relevance as a promising intervention for MI patients.

Keywords: Cardiac patch, engineered heart tissue, regenerative medicine, acute myocardial infarction, cardioprotection, stem cell therapy

Acute myocardial infarction

Acute myocardial infarction (AMI) and the often-ensuing heart failure (HF) are leading causes of morbidity and mortality globally, exerting huge burdens on healthcare and economy (Reed et al., 2017). MI occurs as a result of cardiomyocyte death due to prolonged ischemia and is clinically classified based on the presence or absence of ST-segment elevation on the electrocardiogram (ECG) – ST-elevation MI (STEMI) and non-STEMI (NSTEMI) (Anderson and Morrow, 2017).

Reperfusion, using either thrombolytic therapy or percutaneous coronary intervention (PCI), is mandatory following AMI to salvage ischemic cell death and improve clinical outcome (Saleh and Ambrose, 2018), with the latter being the method of choice (Grines et al., 2003). With reperfusion along with appropriate medical and lifestyle intervention, most patients can be discharged within two to

three days and resume normal or near normal lives (Saleh and Ambrose, 2018). While reperfusion reduces myocardial ischemic injury and limits the infarct size, the process of reperfusion independently activates a cascade of cellular injuries and exacerbates myocardial injury (Shin et al., 2017), causing excessive cardiomyocyte cell death and increasing the infarct size. This phenomenon, termed myocardial reperfusion injury, was shown to contribute to up to 50% of the final infarct size (Yellon and Hausenloy, 2007). The lost cardiomyocytes are replaced by non-contractile scar tissue consisting of cardiac fibroblasts and collagen (Jugdutt, 2009). Though scar formation preserves structural integrity, excessive collagen deposition can cause cardiomyocyte atrophy and arrhythmogenicity (Leask, 2015). Therefore, despite effective reperfusion therapy, survivors remain at risk of severe sequelae, including sudden cardiac death (SCD), HF, and left ventricular systolic

¹National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore. Author affiliation. ²Cardiovascular and Metabolic Disorders Programme, Duke-NUS Medical School, Singapore. ³Yong Loo Lin Medical School, National University of Singapore, Singapore. ⁴National Dental Research Institute Singapore, National Dental Centre Singapore, Singapore

*Both authors contributed equally

Correspondence should be addressed to Dr. Sauri Hernandez-Resendiz (sauri.hdz@duke-nus.edu.sg).

dysfunction (Docherty et al., 2020), prompting the need for new therapies against AMI.

Given that the heart has very limited capacity for regeneration (van Berlo and Molkentin, 2014), stem cell transplantation has emerged as a promising avenue to improve function following myocardial insult (Bartunek et al., 2013; Suncion et al., 2014; Perin et al., 2015; Bartunek et al., 2017; Emmert et al., 2017; Yau et al., 2019). Some clinical trials have yielded positive results, showing improved left ventricular ejection fraction (LVEF) – a major determinant of long-term prognosis for STEMI – following administration of mesenchymal stem cells (MSC) (Kim et al., 2018) and bone marrow mononuclear stem cells (Stamm et al., 2007; Laguna et al., 2018). The benefit of stem cell transplantation extends beyond myocardial regeneration, and include angiogenesis (Tse et al., 2003; Li et al., 2010), and improvements in tissue perfusion and fibrotic burden (Karantalis et al., 2014). However, several recent clinical trials have yielded neutral results with no significant LVEF improvements (Nasser et al., 2014; Wollert et al., 2017; Laguna et al., 2018; Nicolau et al., 2018; Traverse et al., 2018) (see Table 1).

Stem cell transplantation

Following MI, up to one billion cardiomyocytes in the infarct zone are lost (Lin and Pu, 2014). Over the past two decades, studies have attempted to replace the lost myocardial cells using cell injection. However, poor inferior cell engraftment and cell survival at the ischemic region coupled with rapid (hours to days following transplantation) cell loss have resulted in the low efficacy of stem cell therapy (Nguyen et al., 2016).

Stem cell transplantation has yielded promising results (Liu et al., 2018). However, it appears current stem cell transplantation has yet to reach its full potential of alleviating cardiac injury. Several limitations have been eluded from previous studies, with the major limitation being poor cell survival and retention at the intended site (Hou et al., 2005; Sekine et al., 2011; Wang et al., 2013; Lepperhof et al., 2014; Roche et al., 2014; Yan et al., 2017) limiting the regenerative application of stem cell therapy. Furthermore, the harsh ischemic microenvironment of the injured myocardium is not favorable for the transplanted cells (Hu et al., 2016). Efforts to circumvent this include the use of intrinsic cellular homing (such as sphingosine-1 phosphate-sphingosine-1 phosphate receptor 2 (S1P-S1PR2) axis in Muse cells) (Yamada et al., 2018), nanoparticles to facilitate homing of cells (Huang et al., 2013; Lee et al., 2020), and cardiac patch (Roche et al., 2014; Bellamy et al., 2015; Zhang, 2015; Sugiura et al., 2016). While the former two entail a less invasive approach to improve cell retention, they do not necessarily improve the microenvironment to encourage cell survival. On the other hand, cardiac patch, which employs the use of biomaterials, may require more invasive procedures, but the use of biomaterials could provide a more favorable microenvironment to improve cell survival (Sun et al., 2020). Herein we review the recent progress on cardiac patches and discuss how it remains a promising endeavour to alleviate post-MI sequelae.

Cardiac patch

In contrast to cell therapy alone, cardiac patch is a three-dimensional heart tissue engineered *in vitro* and implanted over the infarcted tissue. It has been widely reported to enhance cell retention and survival at the implanted sites, thereby increasing the success of cell therapies (Madonna et al., 2019). Several animal studies have shown the effectiveness of cardiac patch in alleviating cardiac injury in MI (Table 2). A recent study has demonstrated the high degree of retention and vascularization over 14 days of transplanted cardiac patches that were printed with bioinks (composed of cardiac extracellular matrix (cECM),

human heart progenitor cells (hCPCs), and gelatin methacrylate (GelMA) in rat models of MI (Bejleri et al., 2018). The effectiveness of cardiac patches was also seen in a study using a porcine model of MI, where a pair of clinically relevant cardiac patches containing trilineage cardiac cells had engraftment rates beyond 10% at four weeks post-implant and was associated with significant improvements of the left ventricular function coupled with reduced infarct size and myocardial wall stress in the peri-scar boarder zone of the myocardium (Gao et al., 2018). To date, there are only a few human studies being done that used cardiac patch to alleviate post-infarct sequelae (Menasche et al., 2015; Menasche et al., 2018; Prat-Vidal et al., 2020).

The earliest cardiac patch that was implanted in a human contained cardiac-committed human embryonic stem cells (hESCs) – Isl-1+ SSEA-1+ (stage-specific embryonic antigen-1) cells – embedded in a fibrin scaffold. The 68-year-old patient presented with HF as a result of a previous MI, and was designated for surgical anterior myocardial revascularization via coronary artery bypass graft (CABG). During the CABG, the cardiac patch was secured between the pericardium and epicardium with the use of sutures. Functional improvements were observed after three months, with the patient having increased LVEF, 6 min walking distance, and decreased LV end-diastolic and end-systolic volumes (Menasche et al., 2015). Though these improvements were only seen in one patient, the authors conducted a similar study subsequently on six patients with severe ischemic LV dysfunction resulting from previous MI. That study yielded similar optimistic results in the aforementioned parameters (Menasche et al., 2018), demonstrating both the efficacy as well as safety of cardiac patches. Moving forward, the recent first-in-human study scaled up a 2 cm² preclinical construct (Galvez-Monton et al., 2017) to a 16 cm² decellularized human pericardial matrix colonized with 12.5 million human viable Wharton's jelly-derived MSCs (WJ-MSCs) (Prat-Vidal et al., 2020). The cardiac patch was applied by surgical glue over non-revascularizable myocardial scar tissue while CABG was being performed for revascularizable regions. The patient showed ~9% reduction in scar mass in the treated area (Prat-Vidal et al., 2020). Cardiac patches offer a promising integrative approach to repair the injured heart following MI, with optimistic results ranging from improvement of cell retention and engraftment to reducing adverse LV remodeling, preventing LV dilation, and thinning, and enhancing LV function (see Table 3). Nonetheless, cardiac patch has its limitation, and is currently not applicable for clinical application (Zhang et al., 2018).

The challenges of patching the heart

The main challenges in engineered heart tissue (EHT), or cardiac patch, includes but are not limited to (1) the optimization of scaffold mechanics and biocompatibility, (2) cell maturation and contractile ability, (3) electromechanical integration, (4) immune rejection, (5) tissue vascularization and oxygen supplementation (Jackson et al., 2020).

Scaffold mechanics and biocompatibility

An ideal scaffold for cardiac tissue engineering should possess excellent mechanical properties and electrical conductivity to perform normal physiological functions of the heart (Qasim et al., 2019b). Thus, an ideal scaffold must possess sufficient porosity for cell ingrowth (Loh and Choong, 2013; Bruzauskaite et al., 2016), architecture that facilitate proper cardiomyocyte alignment (Homma et al., 2020), mechanical properties to withstand surgical implantation, and surface characteristics to support firm cell adhesion and growth (Prasad and Krishnan, 2008; Khalili and Ahmad, 2015). Recent advances in biomaterials have provided a variety of different approaches to create scaffolds for tissue engineering, which include the use of nanofibers (Joshi and Kothapalli, 2015), hydrogels (El-Sherbiny

Table 1. Clinical trials of stem cell therapy against MI in the recent five years

Year	Randomized	Trials	Arms	Number	Type of cells	Route of delivery	Follow-up	LVEF variation (Study vs Control)	Reference
Positive Results									
2020	Yes	NCT02870933	Receive CD133 ⁺ cells and CABG; CABG alone	30	CD133 ⁺ bone marrow stem cells	Trans-epicardial and transeptal implantation	6 months	$\Delta=8.69\%$ vs -1.43% , $p=0.04$	(Soetisna et al., 2020)
2020	Yes	MSC-HF (NCT00644410)	Bone marrow-derived mesenchymal stem cells (MSCs); Placebo	60	Bone marrow-derived mesenchymal stromal cells	Intramyocardial injection	12 months	$\Delta=5.2\%$ vs -1.0% , $p<0.0001$	(Mathiasen et al., 2020)
2018	Yes	COMPARE CPM-RMI (NCT01167751)	CD133 ⁺ cells; bone marrow mononuclear cells; Placebo	77	CD133 ⁺ bone marrow stem cells or bone marrow mononuclear cells	Intramyocardial injection	18 months	Δ (CD133 ⁺ , placebo) = 8.962 $p=0.011$; Δ (MNC, placebo) = 6.917 $p=0.022$	(Nasari et al., 2018)
Neutral Results									
2021	Yes	CardiAMP Heart Failure (NCT02438306)	Bone marrow mononuclear cells; Sham	250	Bone marrow mononuclear cells	Trans-endocardial injection	12 months	Outcome pending	(Raval et al., 2021)
2020	Yes	CHART-1 (NCT01768702)	Cardiopoietic stem cells; Sham	315	Cardiopoietic stem cells	Intramyocardial injection	2 years	Neutral at 52 weeks	(Bartunek et al., 2020)
2019	Yes	TEAM-AMI (NCT03047772)	Routine atorvastatin (ATV) (20 mg/d) with placebo or bone marrow MSCs (MSC ^{BM}) and intensive ATV (80 mg/d) with placebo or MSC ^{BM}	100	Bone marrow mesenchymal stem cells	Intracoronary infusion	12 months	Outcome pending	(Xu et al., 2019)
2019	Yes	MyStromalCell (NCT01449032)	Adipose-derived stromal cell in border zone; Placebo	60	Adipose-derived stromal cells	Intramyocardial injection	3 years	Exercise tolerance s benefit not clear	(Qayyum et al., 2019)
2019	Yes	SCIENCE (NCT02673164)	Allogeneic cardiology stem cell centre-adipose derived stem cells; Placebo	133	Allogeneic cardiology stem cell centre-adipose derived stem cells	Intramyocardial injection	6 months	Outcome pending	(Paitazoglu et al., 2019)
2018	Yes	CAREMI (NCT02439398)	Allogeneic cardiac stem cells; Placebo	49	Allogeneic cardiac stem cells	Intracoronary infusion	12 months	$\Delta=7.7\%$ vs 8.6% , $p=ns$	(Fernandez-Aviles et al., 2018)
2018	Yes	TIME (NCT00684021)	Bone marrow mononuclear cells post PCI (3 days); placebo	120	Bone marrow mononuclear cells	Intracoronary infusion	2 years	$\Delta=2.8\%$ vs 4.7% , $p=ns$	(Traverse et al., 2018)
2017	No	NCT02387723	Allogeneic adipose derived stem cells	10	Allogeneic adipose derived stem cells	Intramyocardial injection	6 months	$\Delta=2.9\%$ (95% CI: 0.2 to 6.1; $p=0.065$)	(Kastrup et al., 2017)
2017	Yes	PERFECT (NCT00950274)	CD133 ⁺ cells and CABG; Placebo and CABG	82	CD133 ⁺ bone marrow stem cells	Intramyocardial injection	180 days	$\Delta=10.4\%$ vs 8.8% , $p=ns$	(Steinhoff et al., 2017)
2017	Yes	BOOST-2 (ISRCTN17457407)	High-dose (hi)BMCs, low-dose (lo)BMCs, irradiated hiBMCs, or irradiated loBMCs; Placebo	153	Nucleated bone marrow cells	Intracoronary infusion	6 months	$\Delta=(hiBM Cs) 4.3\%$ vs (Control) 3.3% , $p=ns$	(Wollert et al., 2017)
2016	Yes	SWISS-AMI (NCT00355186)	Bone marrow mononuclear cells post PCI (5-7 days OR 3-4 weeks); Sham	200	Bone marrow mononuclear cells	Intracoronary infusion	12 months	$\Delta=-0.9\%$ vs -0.7% vs -1.9% , $p=ns$	(Surder et al., 2016)
2016	Yes	REGENERATE-AMI (NCT00765453)	Bone marrow-derived cells within 24h post PCI; Placebo	100	Bone marrow-derived cells	Intracoronary infusion	1 year	$\Delta=5.1\%$ vs 2.8% , $p=ns$	(Choudry et al., 2016)

and Yacoub, 2013; Radhakrishnan et al., 2014), injectable gels (Alagarsamy et al., 2019), decellularization (Rana et al., 2017; Daley et al., 2018), and 3D printing (Mosadegh et al., 2015; Qasim et al., 2019a). Among which, generating scaffolds from decellularization have been particularly attractive as it preserves the structural “blueprint” of the actual heart. In a breakthrough study in 2008, researchers successfully created a physiologically functional heart by first decellularizing the rat whole heart via coronary perfusion and later incorporating the decellularized scaffolds with cardiac and endothelial cells (Ott et al., 2008). Subsequently, in 2016, researchers successfully repopulated decellularized human myocardial slices (200 μ m thick with hiPSC-CMs) to generate myocardial tissue capable of spontaneous contraction (Guyette et al., 2016). More recently, a pre-clinical study on swine models of MI demonstrated that the implantation of such cardiac patch led to restoration of ventricular function and better recovery following

MI. The cardiac patch was made of decellularized myocardial and pericardial tissues that were repopulated with adipose tissue derived MSCs (Perea-Gil et al., 2018).

However, decellularization and repopulation of cells are not without imperfections. The balance between the removal of cellular components and preservation of structural and biomechanical integrity of the three-dimensional extracellular matrix remains to be optimized (Di Meglio et al., 2017; Kc et al., 2019). Other challenges of using decellularized extracellular matrix (dECM) includes the homogenous distribution of repopulated cells within the scaffold compartments, and the diffusion limit of thick cardiac dECM (Kc et al., 2019).

Other noteworthy innovation includes the recent three-dimensional (3D) bioprinting, which uses a layer-by-layer approach to deposit bioink filaments to generate cardiac patches (Gardin et al., 2020). The advent of additive manufacturing 3D bioprinting technology allows heterogenous cell types,

Table 2. Recent preclinical studies of cardiac patch

Year	Species	Material of patch	Type of cells	Route of delivery	Follow-up	LVEF improvement	Infarct size reduction	Other benefits	Reference
2021	Rat	Oxidized alginate(OA)/gelatin(Geln)/polyacrylic acid(PAA) hydrogel	Rat neonatal cardiomyocytes	Epicardial implantation	4 weeks	Around 25% increase in LVEF compare to MI group, p<0.001	Decreased from 82.73% (in MI group) to 33.25%, p<0.01	Increased arterioles and micro-vessels densities	(Song et al., 2021)
2021	Rat	ECJM hydrogel (made by decellularized heart tissues)	hiPSC-CPCs	Intrapericardial injection	4 weeks	Increased from 29.4% (in MI group) to 45.4%, p<0.0001	Decreased from 38.99% (in MI group) to 18.97%, p<0.0001	Mitigated immune response and increased cells retention	(Zhu et al., 2021)
2021	Rat	Decellularized placenta	hiPSC-CMs	Epicardial implantation	4 weeks	Around 15% increase in LVEF as compared to MI group, p<0.05	Decreased from 20% (in MI group) to 12%, p<0.05	Promoted neovascularization	(Jiang et al., 2021)
2021	Rat	Acetylated chitosan hydrogel	-	Epicardial implantation	1 month	Maximum 40% increase in LVEF as compared to MI group, p<0.01	-	Attenuated fibrosis and inflammation	(Domenge et al., 2021)
2020	Mouse	3D printed scaffold with gelatin methacrylate(GelMA) and polyethylene glycol diacrylate(PEGDA) inks	hiPSC-CMs, hECs, hMSCs	Epicardial implantation	4 months	Increased from 56.1% (in MI group) to 64.1%, but no change as compared to cell only group	Decreased from 14.3% (in MI group) to 5.6%	Increased vascularization and vascular remodelling	(Cui et al., 2020)
2020	Rat	Alginate microspheres and collagen	hiPSC-CMs	Epicardial implantation	1 month	18.6% increase in LVEF as compared to MI group, p=0.006	No significant change in infarct area size	Robust angiogenesis and neovascularization	(Munarin et al., 2020)
2020	Rat/Pig	Decellularized porcine myocardial extracellular matrix	Secreted factor from human cardiac stromal cells	Epicardial implantation	21 days (rats); 7 days (pigs)	Rat-around 20% increase in LVEF as compared to MI group, p<0.0001; Pig-around 5% increase in LVEF as compared to MI group, p<0.05;	Rat-decreased from 30% (in MI group) to 18%, p<0.01; Pig-decreased infarct area on some heart slices	Promoted angiomyogenesis	(Huang et al., 2020)
2019	Rat	Dopamine(DOPA)-coated Polypyrrole(PPy)/poly(glycolic acid)(PGA)	-	Epicardial injection	4 weeks	Around 20% increase in LVEF as compared to MI group, p<0.01	Decreased from 55% (in MI group) to 20%, p<0.001	-	(Song et al., 2019)
2018	Mouse	Elastic hydrogel(EH)/aligned nanocollagen fibrous(AF)/nanogold(AuNPs)	Rat neonatal ventricular myocytes	Epicardial implantation	4 weeks	Around 12% increase in LVEF as compared to MI group, p<0.001	Decreased the scar size of around 25%, p=0.04	Increased vascularization and positive connexin-43 discs	(Hosoyama et al., 2018)
2018	Rat	Hyperbranched poly(amino ester)(HPAE)-pyrrole(Py)/Gelatin and Fe ³⁺	-	Epicardial painting (a novel technique)	4 weeks	Around 25% increase in LVEF as compared to MI group, p<0.01	Decreased from 50% (in MI group) to 15%, p<0.01	Boosted the transmission of electrophysiological signals and promoted revascularization	(Liang et al., 2018)
2018	Pig	Fibrin	hiPSC-CMs, hiPSC-SMCs, hiPSC-ECs	Epicardial implantation	4 weeks	Around 10% increase in LVEF as compared to MI group, p<0.05	Decreased from 10% (in MI group) to 8%, p<0.05	Promoted angiogenesis and cell survival in the peri-scar border zone	(Gao et al., 2018)

biomaterials, and signalling factors to be precisely deposited and arranged in organized geometries similar to those found in the native counterparts (Alonzo et al., 2019). Some of the biomaterials that were utilized for myocardial tissue printing include alginate ((Rastogi and Kandasubramanian, 2019), collagen (Jakab et al., 2008), gelatin (Gaetani et al., 2015), fibrin (Barsotti et al., 2011), and synthetic biomaterials (Ho et al., 2017). Not surprisingly, 3D bioprinting has been explored in the context of dECM (Pati et al., 2014). Three-dimensional printed dECM-based cardiac patch retains the microenvironmental cues that facilitates cardiomyocyte differentiation and maturation (Das et al., 2019). Such results were echoed in another recent study that derived dECM from porcine heart. Human MSCs were then printed onto porcine dECM to generate the cardiac patch, which was implanted on the epicardial infarct region of a rat model of MI. The implanted patch provided a conducive microenvironment and paracrine factors that promote vascular regeneration, resulting in restoration of cardiac function (Park et al., 2019).

Cell maturation and contractile ability

One of the early limitations of using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) is their immature phenotype. Since then, many have attempted to facilitate the maturation of hiPSC-CMs to achieve a more adult-like phenotype – including extended culture, electrical and mechanical stimulation, extracellular matrix modulation, and using microRNAs (Ramachandra et al., 2021). In the context of serum-free culture, several factors were identified to be crucial for the maturation of hiPSC-

CMs. These include triiodothyronine (T3), insulin-like growth factor 1(IGF-1), and glucocorticoid dexamethasone. T3 is essential for cardiomyocyte excitability and contractility was found to enhance the resting membrane potential while IGF-1 and dexamethasone produce synergistic effects on cellular bioenergetics and traction force (Birket et al., 2015). Additionally, further functional and metabolic maturation of hiPSC-CMs were observed when these three factors were coupled with peroxisome proliferator-activated receptor alpha (PPAR- α) activation and hypoxia inducible factor-1 alpha (HIF-1 α) inhibition (Gentillon et al., 2019). Direct supplementation of metabolic substrate such as palmitate/oleate (fatty acids) was also found to promote metabolic maturation of hiPSC-CMs, with better mitochondrial oxidative phosphorylation, and ATP production (Ramachandra et al., 2018).

Interestingly, 3D cultures of hiPSC-CMs generate greater mitochondrial mass as compared to 2D hiPSC-CMs cultures, and produce mitochondrial proteomic profiles similar to adult human cardiomyocytes (Ulmer et al., 2018). By combining different cell populations – hiPSC-CMs, cardiac fibroblasts, and cardiac endothelial cells – maturation is further enhanced, where 3D cultures of hiPSC-CMs exhibit improved sarcomeric structures with transverse tubules, greater contractility and mitochondrial respiration, and more mature electrophysiological properties. The study found that the enhanced maturation was associated with the coupling of hiPSC-CMs with cardiac fibroblast via connexin 43 (CX43) gap junctions and increased intracellular cAMP (Giacomelli et al., 2020). Similarly, co-culturing hiPSC-CMs with MSCs showed improved contractile properties, with the hiPSC-CMs exhibiting aligned myofibrils

Table 3. Clinical trials of cardiac patch implantation against MI

Year	Randomized	Trials	Intervention	Number	Type of cells	Route of delivery	Follow-up	LVEF variation (Study vs Control)	Reference
2020	No	PERISCOPE (NCT03798353)	Decellularized pericardial matrix colonized with human viable Wharton's jelly-derived mesenchymal stromal cells	1	Allogeneic Wharton's jelly-derived MSCs	Surgical epicardial surface delivery	3 months	Reduction of scar mass, LVEF benefit not clear	(Prat-Vidal et al., 2020)
2018	No	ESCORT (NCT02057900)	hESC-derived cardiovascular progenitors embedded fibrin patch	6	hESC-derived cardiovascular progenitors	Epicardial delivery during CABG	12 months	26%(IQR:22-32%) to 38.5%(IQR:33.5-41%) p=ns	(Menasche et al., 2018)
2017	No	UMIN000003273	Scaffold-free cell sheets derived from skeletal muscle	15	Skeletal muscle	Surgical epicardial surface delivery	12 months	26.74±8.0% to 30.7±10.0% p<0.01	(Miyagawa et al., 2017)

with A-, H-, and I-bands that are able to contract and relax rapidly (Yoshida et al., 2018).

Remarkably, the microenvironment has a huge impact on cardiomyocyte maturation, where myocardial-grafted cardiac patch resulted in nascent tissue-like organization with aligned cardiomyocytes in the scaffold that was accompanied by a greater degree of neovascularization and microvascular maturation as compared to the peripherally grafted cardiac patch (Ja et al., 2018). In addition, hiPSC-CMs alone may not be optimal for cardiac regeneration. In particular, a stem cell study showed that when injected into the peri-infarcted anterior free wall of a murine model of MI, hiPSC-derived cardiac progenitors provided greater protection compared to hiPSC-CMs, resulting in greater functional recovery of the heart (Ja et al., 2016). By incorporating hiPSC-CMs with human dermal fibroblasts into fibrin hydrogels and applying electrical stimulation to induce auxotonic contractions, the cardiac patch exhibit adult-like gene expression profiles, organized ultrastructure, sarcomere length, and mitochondrial density. Functionally, these cardiac patches have a positive force-frequency relationship and functional calcium handling. Cardiomyocyte elongation and alignment were facilitated by the passive tension created by the stretching motion within the cardiac patch (Ronaldson-Bouchard et al., 2018). Also, instead of electrical stimulation, a separate study has stimulated similar cardiac patch using a dynamic (rocking) platform, and also resulted in matured cardiomyocytes – with presence of intercalated disk-like structures (Gao et al., 2018).

Moreover, it seems that the presence of other cell population, such as endothelial cells, smooth muscle cells, and MSCs, may significantly improve the contractility (Burrige et al., 2014) and therapeutic effects (Ye et al., 2014) of cardiac patches.

Electromechanical Integration

Besides the cellular immaturity of cardiac patches, another important hurdle to overcome is the electromechanical integration between the implanted cardiac patch and the host myocardium since contraction-competent cardiac patches may disrupt the cardiac syncytium and de-synchronize cardiac rhythm, and potentially exacerbate cardiac arrhythmia, which could lead to pathological conditions (Puig-Sanvicens et al., 2015). Non-human primate studies have shown that the direct injection of hiPSC-CMs has the potential to cause dangerously abnormal ventricular electrical activities (Chong et al., 2014), while epicardial injection of hESC-CMs resulted in graft-induced arrhythmias (Liu et al., 2018).

To tackle this, conductive polymers – such as polydimethylsiloxane (Jackman et al., 2018), polypyrrole (Cui et al., 2018), and poly-3-amino-4-methoxybenzoic acid (Zhang et al., 2020) – were incorporated into the scaffolds (Solazzo et al., 2019). A recent study has demonstrated that an injection of conductive polypyrrole-chitosan hydrogel into the scar zone following MI improved the electrical conduction across the fibrotic scar and resynchronized the cardiac contraction of the

rat's heart (He et al., 2020). Another study conjugated a choline-based bio-ionic liquid onto gelatin methacryloyl to generate a scaffold with better conductive and adhesive property. After which, primary cardiomyocytes and cardiac fibroblasts were incorporated into the scaffold, and the resulting cardiac patch attenuated post-MI remodeling in murine hearts (Walker et al., 2019).

Taken together, conductive scaffolds offer a platform to improve the electromechanical integration of cardiac patches while improving the synchronization of cardiac contraction. Nonetheless, further research is required to optimize the conductivity of cardiac patches to achieve similar properties of the native heart (Baei et al., 2020).

Immune rejection

Immunogenicity is expected to be less of a problem in clinical practice because hiPSC-CMs can be generated from the patient's own somatic cells. However, the urgency for prompt treatment following MI to minimize cardiac injury (Lesneski, 2010) precludes the use of autologous hiPSC-CMs as a substantial amount of time is needed for hiPSC reprogramming and subsequent differentiation into hiPSC-CMs (Blair and Barker, 2016; Lipsitz et al., 2016). On the other hand, while using pre-made allogeneic hiPSC-CMs for cardiac patches is more practical, it runs the risk of immune rejection due to the human leukocyte antigen (HLA) – the human major histocompatibility complex (MHC) (de Rham and Villard, 2014). Thus, the risk versus benefit ratio of the use of hiPSC-CMs remains highly debatable.

By inactivating MHC class I and II genes and overexpressing CD47, researchers were able to generate hypoimmunogenic hiPSCs that retained the ability to differentiate into spontaneously beating hiPSC-CMs (Deuse et al., 2019). This opens the exciting possibility of having a universally compatible source of readily available hiPSC-CMs for regenerative medicine. Alternatively, the use of MHC haplotype homozygous cells could also overcome immunorejection for allogeneic hiPSC-CM transplantation (Kawamura et al., 2016), with a recent clinical study demonstrating the usefulness of hiPSC banking for hematologic and nonhematologic malignancies (Morishima et al., 2020). All of the paired 39 donor HLA homozygous donor to patient heterozygous, except one (early death), engrafted neutrophils (the primary outcome of the study) with incidence of acute graft-versus-host disease of 17/38 (grades II to IV) and 3/38 (grades III to IV). The study concluded that HLA-homo hiPSC transplantation led to favorable engraftment (Morishima et al., 2020). More interestingly, a recent study demonstrated that syngeneic MSCs reduces immune rejection after transplantation of allogeneic hiPSC-CMs in mice (Yoshida et al., 2020). Such findings add to the aforementioned benefits of incorporating MSCs (i.e., enhanced maturation and cardioprotection) in cardiac patches. Furthermore, syngeneic MSCs can be readily harvested using methods such as AdiPrep® (Dragoo and Chang, 2017).




Figure 1. Schematic description of the mechanistic action of cardiac patch. The major mechanisms include (A) providing structural support, (B) promoting direct myocardial remuscularization, and (C) producing cardioprotective paracrine factors. (A) Since a thin fibrotic scar replaces the myocardium at the infarct zone, the rigid scaffold of the cardiac patch provides additional wall thickness and rigidity, which could enhance myocardial function while preventing detrimental left ventricular remodeling. (B) With the tremendous loss of cardiomyocytes following AMI, early studies focus on regenerating the injured myocardium by introducing cells with therapeutic properties. While there were optimistic results that implanted cells were able to reduce the infarct size and stimulate vascularization, there were also contrasting results that showed partial remuscularization with suboptimal biophysical integration of the cardiac patch. Currently, more evidence is attributing the cardioprotective effects of cardiac patch to the paracrine factors produced by the implanted cells. (C) The implanted cells such as adult stem cells which secrete a variety of paracrine factors which is capable of altering the myocardial microenvironment and influence myocardial remodeling.

Vascularization and oxygen supply

Poor perfusion of cardiac patches remains a major issue for cells-containing cardiac patches. Previously, because of the lack of vasculature, the viable cardiac cell sheet-layered tissues were limited to three layers (~80 μm) (Shimizu et al., 2006). Moreover, the suboptimal neovascularization and microvascular maturation could be an intrinsic limitation of the current hiPSC-CMs as a study showed that cardiac patch containing human embryonic stem cell-derived cardiomyocytes (hESC-CMs) generated significantly more robust and mature microvasculature as compared to cardiac patches containing hiPSC-CMs (Ja et al., 2018).

Strategies to rapidly perfuse thick, cell-dense cardiac patches to avoid hypoxia and necrosis are critical to support the long-term survival of the implanted cardiac patches (Chang and Niklason, 2017; Tang et al., 2018). Recent advancements have improved the perfusion of cardiac patches. By incorporating different cell types besides hiPSC-CMs, such as endothelial cells and MSCs, the hybrid cardiac patch was able to generate micro-vessels and integrate rapidly with the host (Huang et al., 2019). Recently, the use of microfluidic hydrodynamics focusing has become an interesting strategy to vascularize cardiac patches as researchers were able to construct biomimetic microvessels. Subsequently, these biomimetic microvessels were incorporated into the cardiac patch resulting in a vascularized cardiac patch that has the natural architecture and function of capillaries. When implanted in a rat model of AMI, the cardiac patch induced cardiomyocyte proliferation at the peri-infarct region four-weeks post-treatment with a significant increase in myocardial capillary density as compared to the conventional cardiac patch (Su et al., 2018).

The mechanism of aciton

Structural Support

Following MI, the injured myocardium is replaced by a thin fibrotic scar that increases wall stress in the surrounding tissues. Thus, the addition of wall thickness and rigidity by a cardiac patch may improve myocardial performance and prevent detrimental LV remodeling (Domenech et al., 2016). Decrease infarct size and reduced wall thinning were also seen (in rat model of MI) from a cardiac patch without cardiomyocytes. This fibrin-based, stretch-conditioned cardiac patch served as a proof-of-concept of the benefits conferred by structural support by the scaffold rather than the replenishment of cardiomyocytes (Wendel et al., 2014). In another study, acellular cardiac patches, generated using type I collagen, attenuated LV remodeling with reduced fibrosis and formation of an interconnected blood vessels at the infarct site, resulting in significant protection against cardiac injury at both the anatomical and functional levels following MI (Serpooshan et al., 2013).

Direct remuscularization

The original goal of the cardiac patch is to replace fibrotic scar tissue with electromechanically functional and vascularized tissue (Lakshmanan et al., 2012; Ye et al., 2013). While a study has shown that cardiac patches containing hiPSC-CMs, fibroblasts, and endothelial cells were able to reduce the infarct size and increase the vessel numbers following MI (Yeung et al., 2019), another study (employing a cryo-injury guinea pig model) demonstrated that cardiac patches only resulted in partial remuscularization of the injured heart (Querdel et al., 2021). Given the poor retention and survival of transplanted cells, multiple stem cell transplantation studies

concluded that the functional improvements seen were not due to direct remuscularization but rather the paracrine effects by the transplanted cells (Gnecchi et al., 2006; Takahashi et al., 2006; Uemura et al., 2006; van der Spoel et al., 2012; Zuo et al., 2012; Bao et al., 2017; Wu et al., 2017; Dougherty et al., 2018; Zhu et al., 2018). As more data has emerged, it appears that remuscularization by the cardiac patch is controversial, especially with the suboptimal biophysical integration of the cardiac patch and the host myocardium (Huang et al., 2019). Current research attributes the main contributor of cardioprotective effects by cardiac patches to be the paracrine factors (Hodgkinson et al., 2016). Such a turn of events could be seen as a blessing since clinically relevant cell-based therapy would require billions of cardiomyocytes (Chong et al., 2014; Liu et al., 2018), making it highly laborious and time-consuming.

Paracrine Effect

Current evidence suggests the majority of the benefits associated with cardiac patches likely revolves from the paracrine activity of implanted cells (Qasim et al., 2019b), with a recent study showing the secretome from hiPSCs and MSCs is able to produce significant improvement of cardiac function and remodeling following MI (Alrefai et al., 2019), thereby circumventing the need for exogenous cell implantation. Furthermore, a cardiac patch containing hiPSC-CMs, fibroblasts, and endothelial cells, produced improvement of heart function that is correlated with patch production of extracellular vesicles (i.e. exosomes). In addition, the cardiac patch led to regeneration of cardiac tissues, angiogenesis in the infarcted area, and reduced scar tissue formation (Yeung et al., 2019).

Adult stem cells secrete a variety of growth factors and chemokines - including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and IGF-1 – which alters the microenvironment of the myocardium and regulate remodeling following MI (Hodgkinson et al., 2016; Broughton et al., 2018). To facilitate the direct delivery of the secreted regenerative factors into the injured myocardium, microneedles were engineered on a cardiac patch incorporated with cardiac stromal cells. The resulting cardiac patch effectively augmented the myocardial function and enhanced angiomyogenesis (Tang et al., 2018).

Future directions

With many optimistic results thus far, the cardiac patch remains a promising avenue to pursue to attenuate cardiac injury associated with MI. However, more evidence suggests that the beneficial effects of the cardiac patch are largely due to the non-cellular part of the cardiac patch (Domenech et al., 2016; Qasim et al., 2019b). Therefore, we envision that the next generation of cardiac patch would be an acellular one that is focused on providing structural support while serving as a delivery vehicle for the continuous release of cardioprotective secretomes. Being cell-free not only reduces the risk of immune rejection but overcomes the need for perfusion, electromechanical integration, and cell maturation – all of which are the major roadblocks of today's cardiac patch.

Conclusion

AMI remains as one of the leading causes of death despite tremendous leaps in medical advancements. Over the years, research has led to mechanistic insights on the cardioprotective benefits conferred by cardiac patches. These include (1) providing structural support, (2) promoting direct remuscularization, and (3) secretion of cardioprotective paracrine factors (see Figure 1). Earlier studies have focused on “direct remuscularization”, optimizing the delivery and incorporation of cardiomyocytes and other cell types to the

infarct zone in an attempt to regenerate and repair myocardium. Soon, it became clear that cardiomyocytes were not the only important cell type. Other important cell types include MSCs, cardiac fibroblasts, and endothelial cells. However, increasing evidence have suggested that the key contributors to the protective effects of cardiac patches are the secretomes or exosomes produced by the implanted cells rather than the cells themselves. Therefore, we envision that the next generation of cardiac patches would be an acellular one that deliver protective secretomes. Being acellular would help overcome most of the major obstacles faced by the current cardiac patches. With optimistic data of cardiac patches presented by numerous studies, we believe that the cardiac patch remains a promising avenue to attenuate post-MI sequelae.

Acknowledgements

Sauri Hernandez-Resendiz is supported by the Singapore Ministry of Health's National Medical Research Council under its Open Fund-Young Individual Research Grant (OF-YIRG)-[NMRC/OFYIRG/0078/2018].

References

- Alagarsamy KN, Yan W, Srivastava A, Desiderio V, Dhingra S (2019) Application of injectable hydrogels for cardiac stem cell therapy and tissue engineering. *Rev Cardiovasc Med* 20:221-230.
- Alonzo M, AnilKumar S, Roman B, Tasnim N, Joddar B (2019) 3D Bioprinting of cardiac tissue and cardiac stem cell therapy. *Transl Res* 211:64-83.
- Alrefai MT, Tarola CL, Raagas R, Ridwan K, Shalal M, Lomis N, Paul A, Alrefai MD, Prakash S, Schwertani A, Shum-Tim D (2019) Functional Assessment of Pluripotent and Mesenchymal Stem Cell Derived Secretome in Heart Disease. *Ann Stem Cell Res* 2:29-36.
- Anderson JL, Morrow DA (2017) Acute Myocardial Infarction. *N Engl J Med* 376:2053-2064.
- Baei P, Hosseini M, Baharvand H, Pahlavan S (2020) Electrically conductive materials for in vitro cardiac microtissue engineering. *J Biomed Mater Res A* 108:1203-1213.
- Bao L, Meng Q, Li Y, Deng S, Yu Z, Liu Z, Zhang L, Fan H (2017) C-Kit Positive Cardiac Stem Cells and Bone Marrow-Derived Mesenchymal Stem Cells Synergistically Enhance Angiogenesis and Improve Cardiac Function After Myocardial Infarction in a Paracrine Manner. *J Card Fail* 23:403-415.
- Barsotti MC, Felice F, Balbarini A, Di Stefano R (2011) Fibrin as a scaffold for cardiac tissue engineering. *Biotechnol Appl Biochem* 58:301-310.
- Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, El Nakadi B, Banovic M, Beleslin B, Vrolix M, Legrand V, Vrints C, Vanoverschelde JL, Crespo-Diaz R, Homsy C, Tendera M, Waldman S, Wijns W, Terzic A (2013) Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. *J Am Coll Cardiol* 61:2329-2338.
- Bartunek J et al. (2020) Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes. *ESC Heart Fail*.
- Bartunek J et al. (2017) Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. *Eur Heart J* 38:648-660.
- Bejleri D, Streeter BW, Nachlas ALY, Brown ME, Gaetani R,

- Christman KL, Davis ME (2018) A Bioprinted Cardiac Patch Composed of Cardiac-Specific Extracellular Matrix and Progenitor Cells for Heart Repair. *Adv Healthc Mater* 7:e1800672.
- Bellamy V, Vanneau V, Bel A, Nemetalla H, Emmanuelle Boitard S, Farouz Y, Joanne P, Perier MC, Robidel E, Mandet C, Hagege A, Bruneval P, Larghero J, Agbulut O, Menasche P (2015) Long-term functional benefits of human embryonic stem cell-derived cardiac progenitors embedded into a fibrin scaffold. *J Heart Lung Transplant* 34:1198-1207.
- Birket MJ, Ribeiro MC, Kosmidis G, Ward D, Leitoguinho AR, van de Pol V, Dambrot C, Devalla HD, Davis RP, Mastroberardino PG, Atsma DE, Passier R, Mummery CL (2015) Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function. *Cell Rep* 13:733-745.
- Blair NF, Barker RA (2016) Making it personal: the prospects for autologous pluripotent stem cell-derived therapies. *Regen Med* 11:423-425.
- Broughton KM, Wang BJ, Firouzi F, Khalafalla F, Dimmeler S, Fernandez-Aviles F, Sussman MA (2018) Mechanisms of Cardiac Repair and Regeneration. *Circ Res* 122:1151-1163.
- Bruzauskaite I, Bironaite D, Bagdonas E, Bernotiene E (2016) Scaffolds and cells for tissue regeneration: different scaffold pore sizes-different cell effects. *Cytotechnology* 68:355-369.
- Burridge PW, Metzler SA, Nakayama KH, Abilez OJ, Simmons CS, Bruce MA, Matsuura Y, Kim P, Wu JC, Butte M, Huang NF, Yang PC (2014) Multi-cellular interactions sustain long-term contractility of human pluripotent stem cell-derived cardiomyocytes. *Am J Transl Res* 6:724-735.
- Chang WG, Niklason LE (2017) A short discourse on vascular tissue engineering. *NPJ Regen Med* 2.
- Chong JJ et al. (2014) Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. *Nature* 510:273-277.
- Choudry F, Hamshere S, Saunders N, Veerapen J, Bavnbek K, Knight C, Pellerin D, Locca D, Westwood M, Rakhit R, Crake T, Kastrup J, Parmar M, Agrawal S, Jones D, Martin J, Mathur A (2016) A randomized double-blind control study of early intra-coronary autologous bone marrow cell infusion in acute myocardial infarction: the REGENERATE-AMI clinical trial. *Eur Heart J* 37:256-263.
- Cui H, Liu C, Esworthy T, Huang Y, Yu ZX, Zhou X, San H, Lee SJ, Hann SY, Boehm M, Mohiuddin M, Fisher JP, Zhang LG (2020) 4D physiologically adaptable cardiac patch: A 4-month in vivo study for the treatment of myocardial infarction. *Sci Adv* 6:eabb5067.
- Cui Z, Ni NC, Wu J, Du GQ, He S, Yau TM, Weisel RD, Sung HW, Li RK (2018) Polypyrrole-chitosan conductive biomaterial synchronizes cardiomyocyte contraction and improves myocardial electrical impulse propagation. *Theranostics* 8:2752-2764.
- Daley MC, Fenn SL, Black LD, 3rd (2018) Applications of Cardiac Extracellular Matrix in Tissue Engineering and Regenerative Medicine. *Adv Exp Med Biol* 1098:59-83.
- Das S, Kim SW, Choi YJ, Lee S, Lee SH, Kong JS, Park HJ, Cho DW, Jang J (2019) Decellularized extracellular matrix bioinks and the external stimuli to enhance cardiac tissue development in vitro. *Acta Biomater* 95:188-200.
- de Rham C, Villard J (2014) Potential and limitation of HLA-based banking of human pluripotent stem cells for cell therapy. *J Immunol Res* 2014:518135.
- Deuse T, Hu X, Gravina A, Wang D, Tediashvili G, De C, Thayer WO, Wahl A, Garcia JV, Reichenspurner H, Davis MM, Lanier LL, Schrepfer S (2019) Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. *Nat Biotechnol* 37:252-258.
- Di Meglio F, Nurzynska D, Romano V, Miraglia R, Belviso I, Sacco AM, Barbato V, Di Gennaro M, Granato G, Maiello C, Montagnani S, Castaldo C (2017) Optimization of Human Myocardium Decellularization Method for the Construction of Implantable Patches. *Tissue Eng Part C Methods* 23:525-539.
- Docherty KF, Ferreira JP, Sharma A, Girerd N, Gregson J, Duarte K, Petrie MC, Jhund PS, Dickstein K, Pfeffer MA, Pitt B, Rossignol P, Zannad F, McMurray JJV (2020) Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. *Eur J Heart Fail* 22:848-855.
- Domenech M, Polo-Corrales L, Ramirez-Vick JE, Freytes DO (2016) Tissue Engineering Strategies for Myocardial Regeneration: Acellular Versus Cellular Scaffolds? *Tissue Eng Part B Rev* 22:438-458.
- Domenge O, Ragot H, Deloux R, Crepet A, Revet G, Boitard SE, Simon A, Mougenot N, David L, Delair T, Montembault A, Agbulut O (2021) Efficacy of epicardial implantation of acellular chitosan hydrogels in ischemic and nonischemic heart failure: impact of the acetylation degree of chitosan. *Acta Biomater* 119:125-139.
- Dougherty JA, Kumar N, Noor M, Angelos MG, Khan M, Chen CA, Khan M (2018) Extracellular Vesicles Released by Human Induced-Pluripotent Stem Cell-Derived Cardiomyocytes Promote Angiogenesis. *Front Physiol* 9:1794.
- Dragoo JL, Chang W (2017) Arthroscopic Harvest of Adipose-Derived Mesenchymal Stem Cells From the Infrapatellar Fat Pad. *Am J Sports Med* 45:3119-3127.
- El-Sherbiny IM, Yacoub MH (2013) Hydrogel scaffolds for tissue engineering: Progress and challenges. *Glob Cardiol Sci Pract* 2013:316-342.
- Emmert MY, Wolint P, Jakab A, Sheehy SP, Pasqualini FS, Nguyen TDL, Hilbe M, Seifert B, Weber B, Brokopp CE, Macejovska D, Caliskan E, von Eckardstein A, Schwartlander R, Vogel V, Falk V, Parker KK, Gyongyosi M, Hoerstrup SP (2017) Safety and efficacy of cardiopoietic stem cells in the treatment of post-infarction left-ventricular dysfunction - From cardioprotection to functional repair in a translational pig infarction model. *Biomaterials* 122:48-62.
- Fernandez-Aviles F et al. (2018) Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With ST-Segment Elevation Myocardial Infarction and Left Ventricular Dysfunction. *Circ Res* 123:579-589.
- Gaetani R, Feyen DA, Verhage V, Slaats R, Messina E, Christman KL, Giacomello A, Doevendans PA, Sluijter JP (2015) Epicardial application of cardiac progenitor cells in a 3D-printed gelatin/hyaluronic acid patch preserves cardiac function after myocardial infarction. *Biomaterials* 61:339-348.
- Galvez-Monton C, Bragos R, Soler-Botija C, Diaz-Guemes I, Prat-Vidal C, Crisostomo V, Sanchez-Margallo FM, Lucia-Valldeperas A, Bogonez-Franco P, Perea-Gil I,

- Roura S, Bayes-Genis A (2017) Noninvasive Assessment of an Engineered Bioactive Graft in Myocardial Infarction: Impact on Cardiac Function and Scar Healing. *Stem Cells Transl Med* 6:647-655.
- Gao L, Gregorich ZR, Zhu W, Mattapally S, Oduk Y, Lou X, Kannappan R, Borovjagin AV, Walcott GP, Pollard AE, Fast VG, Hu X, Lloyd SG, Ge Y, Zhang J (2018) Large Cardiac Muscle Patches Engineered From Human Induced-Pluripotent Stem Cell-Derived Cardiac Cells Improve Recovery From Myocardial Infarction in Swine. *Circulation* 137:1712-1730.
- Gardin C, Ferroni L, Latremouille C, Chachques JC, Mitreic D, Zavan B (2020) Recent Applications of Three Dimensional Printing in Cardiovascular Medicine. *Cells* 9.
- Gentillon C, Li D, Duan M, Yu WM, Preininger MK, Jha R, Rampoldi A, Saraf A, Gibson GC, Qu CK, Brown LA, Xu C (2019) Targeting HIF-1 α in combination with PPAR α activation and postnatal factors promotes the metabolic maturation of human induced pluripotent stem cell-derived cardiomyocytes. *J Mol Cell Cardiol* 132:120-135.
- Giacomelli E et al. (2020) Human-iPSC-Derived Cardiac Stromal Cells Enhance Maturation in 3D Cardiac Microtissues and Reveal Non-cardiomyocyte Contributions to Heart Disease. *Cell Stem Cell* 26:862-879 e811.
- Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, Dzau VJ (2006) Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. *FASEB J* 20:661-669.
- Grines CL, Serruys P, O'Neill WW (2003) Fibrinolytic therapy: is it a treatment of the past? *Circulation* 107:2538-2542.
- Guyette JP, Charest JM, Mills RW, Jank BJ, Moser PT, Gilpin SE, Gershlak JR, Okamoto T, Gonzalez G, Milan DJ, Gaudette GR, Ott HC (2016) Bioengineering Human Myocardium on Native Extracellular Matrix. *Circ Res* 118:56-72.
- He S, Wu J, Li SH, Wang L, Sun Y, Xie J, Ramnath D, Weisel RD, Yau TM, Sung HW, Li RK (2020) The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure. *Biomaterials* 258:120285.
- Ho CM, Mishra A, Lin PT, Ng SH, Yeong WY, Kim YJ, Yoon YJ (2017) 3D Printed Polycaprolactone Carbon Nanotube Composite Scaffolds for Cardiac Tissue Engineering. *Macromol Biosci* 17.
- Hodgkinson CP, Bareja A, Gomez JA, Dzau VJ (2016) Emerging Concepts in Paracrine Mechanisms in Regenerative Cardiovascular Medicine and Biology. *Circ Res* 118:95-107.
- Homma J, Shimizu S, Sekine H, Matsuura K, Shimizu T (2020) A novel method to align cells in a cardiac tissue-like construct fabricated by cell sheet-based tissue engineering. *J Tissue Eng Regen Med*.
- Hosoyama K, Ahumada M, McTiernan CD, Davis DR, Variola F, Ruel M, Liang W, Suuronen EJ, Alarcon EI (2018) Nanoengineered Electroconductive Collagen-Based Cardiac Patch for Infarcted Myocardium Repair. *ACS Appl Mater Interfaces* 10:44668-44677.
- Hou D, Youssef EA, Brinton TJ, Zhang P, Rogers P, Price ET, Yeung AC, Johnstone BH, Yock PG, March KL (2005) Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. *Circulation* 112:1150-1156.
- Hu X et al. (2016) A Large-Scale Investigation of Hypoxia-Preconditioned Allogeneic Mesenchymal Stem Cells for Myocardial Repair in Nonhuman Primates: Paracrine Activity Without Remuscularization. *Circ Res* 118:970-983.
- Huang K, Hu S, Cheng K (2019) A New Era of Cardiac Cell Therapy: Opportunities and Challenges. *Adv Healthc Mater* 8:e1801011.
- Huang K, Ozpinar EW, Su T, Tang J, Shen D, Qiao L, Hu S, Li Z, Liang H, Mathews K, Scharf V, Freytes DO, Cheng K (2020) An off-the-shelf artificial cardiac patch improves cardiac repair after myocardial infarction in rats and pigs. *Sci Transl Med* 12.
- Huang Z, Shen Y, Sun A, Huang G, Zhu H, Huang B, Xu J, Song Y, Pei N, Ma J, Yang X, Zou Y, Qian J, Ge J (2013) Magnetic targeting enhances retrograde cell retention in a rat model of myocardial infarction. *Stem Cell Res Ther* 4:149.
- Ja KP, Lim KP, Chen A, Ting S, Li SQ, Tee N, Ramachandra C, Mehta A, Wong P, Oh S, Shim W (2018) Construction of a vascularized hydrogel for cardiac tissue formation in a porcine model. *J Tissue Eng Regen Med* 12:e2029-e2038.
- Ja KP, Miao Q, Zhen Tee NG, Lim SY, Nandihalli M, Ramachandra CJA, Mehta A, Shim W (2016) iPSC-derived human cardiac progenitor cells improve ventricular remodeling via angiogenesis and interstitial networking of infarcted myocardium. *J Cell Mol Med* 20:323-332.
- Jackman CP, Ganapathi AM, Asfour H, Qian Y, Allen BW, Li Y, Bursac N (2018) Engineered cardiac tissue patch maintains structural and electrical properties after epicardial implantation. *Biomaterials* 159:48-58.
- Jackson AO, Rahman GA, Yin K, Long S (2020) Enhancing Matured Stem-Cardiac Cell Generation and Transplantation: A Novel Strategy for Heart Failure Therapy. *J Cardiovasc Transl Res*.
- Jakab K, Norotte C, Damon B, Marga F, Neagu A, Besch-Williford CL, Kachurin A, Church KH, Park H, Mironov V, Markwald R, Vunjak-Novakovic G, Forgacs G (2008) Tissue engineering by self-assembly of cells printed into topologically defined structures. *Tissue Eng Part A* 14:413-421.
- Jiang Y, Sun SJ, Zhen Z, Wei R, Zhang N, Liao SY, Tse HF (2021) Myocardial repair of bioengineered cardiac patches with decellularized placental scaffold and human-induced pluripotent stem cells in a rat model of myocardial infarction. *Stem Cell Res Ther* 12:13.
- Joshi J, Kothapalli CR (2015) Nanofibers based tissue engineering and drug delivery approaches for myocardial regeneration. *Curr Pharm Des* 21:2006-2020.
- Jugdutt BI (2009) Limiting fibrosis after myocardial infarction. *N Engl J Med* 360:1567-1569.
- Karantalis V et al. (2014) Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial. *Circ Res* 114:1302-1310.
- Kastrup J, Haack-Sorensen M, Juhl M, Harary Sondergaard R, Follin B, Drozd Lund L, Monsted Johansen E, Ali Qayyum A, Bruun Mathiasen A, Jorgensen E, Helqvist

- S, Jorgen Elberg J, Bruunsgaard H, Ekblond A (2017) Cryopreserved Off-the-Shelf Allogeneic Adipose-Derived Stromal Cells for Therapy in Patients with Ischemic Heart Disease and Heart Failure-A Safety Study. *Stem Cells Transl Med* 6:1963-1971.
- Kawamura T, Miyagawa S, Fukushima S, Maeda A, Kashiyama N, Kawamura A, Miki K, Okita K, Yoshida Y, Shiina T, Ogasawara K, Miyagawa S, Toda K, Okuyama H, Sawa Y (2016) Cardiomyocytes Derived from MHC-Homozygous Induced Pluripotent Stem Cells Exhibit Reduced Allogeneic Immunogenicity in MHC-Matched Non-human Primates. *Stem Cell Reports* 6:312-320.
- Kc P, Hong Y, Zhang G (2019) Cardiac tissue-derived extracellular matrix scaffolds for myocardial repair: advantages and challenges. *Regen Biomater* 6:185-199.
- Khalili AA, Ahmad MR (2015) A Review of Cell Adhesion Studies for Biomedical and Biological Applications. *Int J Mol Sci* 16:18149-18184.
- Kim SH, Cho JH, Lee YH, Lee JH, Kim SS, Kim MY, Lee MG, Kang WY, Lee KS, Ahn YK, Jeong MH, Kim HS (2018) Improvement in Left Ventricular Function with Intracoronary Mesenchymal Stem Cell Therapy in a Patient with Anterior Wall ST-Segment Elevation Myocardial Infarction. *Cardiovasc Drugs Ther* 32:329-338.
- Laguna G, S DIS, Maroto L, Fulquet E, Echevarria JR, Revilla A, Uruena N, Sevilla T, Arnold R, Ramos B, Gutierrez H, Serrador A, San Roman JA (2018) Effect of direct intramyocardial autologous stem cell grafting in the sub-acute phase after myocardial infarction. *J Cardiovasc Surg (Torino)* 59:259-267.
- Lakshmanan R, Krishnan UM, Sethuraman S (2012) Living cardiac patch: the elixir for cardiac regeneration. *Expert Opin Biol Ther* 12:1623-1640.
- Leask A (2015) Getting to the heart of the matter: new insights into cardiac fibrosis. *Circ Res* 116:1269-1276.
- Lee JR, Park BW, Kim J, Choo YW, Kim HY, Yoon JK, Kim H, Hwang JW, Kang M, Kwon SP, Song SY, Ko IO, Park JA, Ban K, Hyeon T, Park HJ, Kim BS (2020) Nanovesicles derived from iron oxide nanoparticles-incorporated mesenchymal stem cells for cardiac repair. *Sci Adv* 6:eaa0952.
- Lepperhof V, Polchynski O, Kruttwig K, Bruggemann C, Neef K, Drey F, Zheng Y, Ackermann JP, Choi YH, Wunderlich TF, Hoehn M, Hescheler J, Saric T (2014) Bioluminescent imaging of genetically selected induced pluripotent stem cell-derived cardiomyocytes after transplantation into infarcted heart of syngeneic recipients. *PLoS One* 9:e107363.
- Lesneski L (2010) Factors influencing treatment delay for patients with acute myocardial infarction. *Appl Nurs Res* 23:185-190.
- Li H, Zuo S, He Z, Yang Y, Pasha Z, Wang Y, Xu M (2010) Paracrine factors released by GATA-4 overexpressed mesenchymal stem cells increase angiogenesis and cell survival. *Am J Physiol Heart Circ Physiol* 299:H1772-1781.
- Liang S, Zhang Y, Wang H, Xu Z, Chen J, Bao R, Tan B, Cui Y, Fan G, Wang W, Wang W, Liu W (2018) Paintable and Rapidly Bondable Conductive Hydrogels as Therapeutic Cardiac Patches. *Adv Mater* 30:e1704235.
- Lin Z, Pu WT (2014) Strategies for cardiac regeneration and repair. *Sci Transl Med* 6:239rv231.
- Lipsitz YY, Timmins NE, Zandstra PW (2016) Quality cell therapy manufacturing by design. *Nat Biotechnol* 34:393-400.
- Liu YW et al. (2018) Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates. *Nat Biotechnol* 36:597-605.
- Loh QL, Choong C (2013) Three-dimensional scaffolds for tissue engineering applications: role of porosity and pore size. *Tissue Eng Part B Rev* 19:485-502.
- Madonna R et al. (2019) ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure. *Cardiovasc Res* 115:488-500.
- Mathiasen AB, Qayyum AA, Jorgensen E, Helqvist S, Kofoed KF, Haack-Sorensen M, Ekblond A, Kastrup J (2020) Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial. *Eur J Heart Fail* 22:884-892.
- Menasche P, Vanneau V, Hagege A, Bel A, Cholley B, Cacciapuoti I, Parouchev A, Benhamouda N, Tachdjian G, Tosca L, Trouvin JH, Fabreguettes JR, Bellamy V, Guillemain R, Suberbielle Boissel C, Tartour E, Desnos M, Larghero J (2015) Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. *Eur Heart J* 36:2011-2017.
- Menasche P, Vanneau V, Hagege A, Bel A, Cholley B, Parouchev A, Cacciapuoti I, Al-Daccak R, Benhamouda N, Blons H, Agbulut O, Tosca L, Trouvin JH, Fabreguettes JR, Bellamy V, Charron D, Tartour E, Tachdjian G, Desnos M, Larghero J (2018) Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction. *J Am Coll Cardiol* 71:429-438.
- Miyagawa S, Domae K, Yoshikawa Y, Fukushima S, Nakamura T, Saito A, Sakata Y, Hamada S, Toda K, Pak K, Takeuchi M, Sawa Y (2017) Phase I Clinical Trial of Autologous Stem Cell-Sheet Transplantation Therapy for Treating Cardiomyopathy. *J Am Heart Assoc* 6.
- Morishima Y, Morishima S, Murata M, Arima N, Uchida N, Sugio Y, Takahashi S, Matsushashi Y, Onizuka M, Eto T, Nagafuji K, Onishi Y, Inoue M, Atsuta Y, Fukuda T, Ichinohe T, Kato S, Kanda J (2020) Impact of Homozygous Conserved Extended HLA Haplotype on Single Cord Blood Transplantation: Lessons for Induced Pluripotent Stem Cell Banking and Transplantation in Allogeneic Settings. *Biol Blood Marrow Transplant* 26:132-138.
- Mosadegh B, Xiong G, Dunham S, Min JK (2015) Current progress in 3D printing for cardiovascular tissue engineering. *Biomed Mater* 10:034002.
- Munarin F, Kant RJ, Rupert CE, Khoo A, Coulombe KKL (2020) Engineered human myocardium with local release of angiogenic proteins improves vascularization and cardiac function in injured rat hearts. *Biomaterials* 251:120033.
- Naseri MH et al. (2018) COMPARE CPM-RMI Trial: Intramyocardial Transplantation of Autologous Bone Marrow-Derived CD133+ Cells and MNCs during CABG in Patients with Recent MI: A Phase II/III, Multicenter, Placebo-Controlled, Randomized, Double-Blind Clinical Trial. *Cell J* 20:267-277.
- Nasseri BA, Ebell W, Dandel M, Kukucka M, Gebker R, Doltra A, Knosalla C, Choi YH, Hetzer R, Stamm C (2014) Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the

- Cardio133 trial. *Eur Heart J* 35:1263-1274.
- Nguyen PK, Neofytou E, Rhee JW, Wu JC (2016) Potential Strategies to Address the Major Clinical Barriers Facing Stem Cell Regenerative Therapy for Cardiovascular Disease: A Review. *JAMA Cardiol* 1:953-962.
- Nicolau JC, Furtado RHM, Silva SA, Rochitte CE, Rassi A, Jr., Moraes J, Jr., Quintella E, Costantini CR, Korman APM, Mattos MA, Castello HJ, Jr., Caixeta A, Dohmann HFR, de Carvalho ACC, MiHeart AMII (2018) Stem-cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double-blind randomized trial. *Clin Cardiol* 41:392-399.
- Ott HC, Matthiesen TS, Goh SK, Black LD, Kren SM, Netoff TI, Taylor DA (2008) Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. *Nat Med* 14:213-221.
- Paitazoglou C, Bergmann MW, Vrtovec B, Chamuleau SAJ, van Klarenbosch B, Wojakowski W, Michalewska-Wludarczyk A, Gyongyosi M, Ekblond A, Haack-Sorensen M, Jaquet K, Vrangbaek K, Kastrup J, Investigators S (2019) Rationale and design of the European multicentre study on Stem Cell therapy in Ischemic Non-treatable Cardiac disease (SCIENCE). *Eur J Heart Fail* 21:1032-1041.
- Park SJ, Kim RY, Park BW, Lee S, Choi SW, Park JH, Choi JJ, Kim SW, Jang J, Cho DW, Chung HM, Moon SH, Ban K, Park HJ (2019) Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction. *Nat Commun* 10:3123.
- Pati F, Jang J, Ha DH, Won Kim S, Rhie JW, Shim JH, Kim DH, Cho DW (2014) Printing three-dimensional tissue analogues with decellularized extracellular matrix bioink. *Nat Commun* 5:3935.
- Perea-Gil I, Galvez-Monton C, Prat-Vidal C, Jorba I, Segu-Verges C, Roura S, Soler-Botija C, Iborra-Egea O, Revuelta-Lopez E, Fernandez MA, Farre R, Navajas D, Bayes-Genis A (2018) Head-to-head comparison of two engineered cardiac grafts for myocardial repair: From scaffold characterization to pre-clinical testing. *Sci Rep* 8:6708.
- Perin EC, Borow KM, Silva GV, DeMaria AN, Marroquin OC, Huang PP, Traverse JH, Krum H, Skerrett D, Zheng Y, Willerson JT, Itescu S, Henry TD (2015) A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure. *Circ Res* 117:576-584.
- Prasad CK, Krishnan LK (2008) Regulation of endothelial cell phenotype by biomimetic matrix coated on biomaterials for cardiovascular tissue engineering. *Acta Biomater* 4:182-191.
- Prat-Vidal C et al. (2020) First-in-human PeriCord cardiac bioimplant: Scalability and GMP manufacturing of an allogeneic engineered tissue graft. *EBioMedicine* 54:102729.
- Puig-Sanvicens VA, Semino CE, Zur Nieden NI (2015) Cardiac differentiation potential of human induced pluripotent stem cells in a 3D self-assembling peptide scaffold. *Differentiation* 90:101-110.
- Qasim M, Haq F, Kang MH, Kim JH (2019a) 3D printing approaches for cardiac tissue engineering and role of immune modulation in tissue regeneration. *Int J Nanomedicine* 14:1311-1333.
- Qasim M, Arunkumar P, Powell HM, Khan M (2019b) Current research trends and challenges in tissue engineering for mending broken hearts. *Life Sci* 229:233-250.
- Qayyum AA, Mathiasen AB, Helqvist S, Jorgensen E, Haack-Sorensen M, Ekblond A, Kastrup J (2019) Autologous adipose-derived stromal cell treatment for patients with refractory angina (MyStromalCell Trial): 3-years follow-up results. *J Transl Med* 17:360.
- Querdel E et al. (2021) Human Engineered Heart Tissue Patches Remuscularize the Injured Heart in a Dose-Dependent Manner. *Circulation*.
- Radhakrishnan J, Krishnan UM, Sethuraman S (2014) Hydrogel based injectable scaffolds for cardiac tissue regeneration. *Biotechnol Adv* 32:449-461.
- Ramachandra CJA, Chua J, Cong S, Kp MMJ, Shim W, Wu JC, Hausenloy DJ (2021) Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies. *Cardiovasc Res* 117:694-711.
- Ramachandra CJA, Mehta A, Wong P, Ja K, Fritsche-Danielson R, Bhat RV, Hausenloy DJ, Kovalik JP, Shim W (2018) Fatty acid metabolism driven mitochondrial bioenergetics promotes advanced developmental phenotypes in human induced pluripotent stem cell derived cardiomyocytes. *Int J Cardiol* 272:288-297.
- Rana D, Zreiqat H, Benkirane-Jessel N, Ramakrishna S, Ramalingam M (2017) Development of decellularized scaffolds for stem cell-driven tissue engineering. *J Tissue Eng Regen Med* 11:942-965.
- Rastogi P, Kandasubramanian B (2019) Review of alginate-based hydrogel bioprinting for application in tissue engineering. *Biofabrication* 11:042001.
- Raval AN, Johnston PV, Duckers HJ, Cook TD, Traverse JH, Altman PA, Dhingra R, Hematti P, Borrello I, Anderson RD, Pepine CJ (2021) Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort. *Int J Cardiol* 326:131-138.
- Reed GW, Rossi JE, Cannon CP (2017) Acute myocardial infarction. *Lancet* 389:197-210.
- Roche ET, Hastings CL, Lewin SA, Shvartsman D, Brudno Y, Vasilyev NV, O'Brien FJ, Walsh CJ, Duffy GP, Mooney DJ (2014) Comparison of biomaterial delivery vehicles for improving acute retention of stem cells in the infarcted heart. *Biomaterials* 35:6850-6858.
- Ronaldson-Bouchard K, Ma SP, Yeager K, Chen T, Song L, Sirabella D, Morikawa K, Teles D, Yazawa M, Vunjak-Novakovic G (2018) Advanced maturation of human cardiac tissue grown from pluripotent stem cells. *Nature* 556:239-243.
- Saleh M, Ambrose JA (2018) Understanding myocardial infarction. *F1000Res* 7.
- Sekine H, Shimizu T, Dobashi I, Matsuura K, Hagiwara N, Takahashi M, Kobayashi E, Yamato M, Okano T (2011) Cardiac cell sheet transplantation improves damaged heart function via superior cell survival in comparison with dissociated cell injection. *Tissue Eng Part A* 17:2973-2980.
- Serpooshan V, Zhao M, Metzler SA, Wei K, Shah PB, Wang A, Mahmoudi M, Malkovskiy AV, Rajadas J, Butte MJ, Bernstein D, Ruiz-Lozano P (2013) The effect of bioengineered acellular collagen patch on cardiac remodeling and ventricular function post myocardial infarction. *Biomaterials* 34:9048-9055.
- Shimizu T, Sekine H, Yang J, Isoi Y, Yamato M, Kikuchi A, Kobayashi E, Okano T (2006) Polysurgery of cell sheet

- grafts overcomes diffusion limits to produce thick, vascularized myocardial tissues. *FASEB J* 20:708-710.
- Shin B, Cowan DB, Emani SM, Del Nido PJ, McCully JD (2017) Mitochondrial Transplantation in Myocardial Ischemia and Reperfusion Injury. *Adv Exp Med Biol* 982:595-619.
- Soetisna TW, Sukmawan R, Setianto B, Mansyur M, Murni TW, Listiyaningsih E, Santoso A (2020) Combined transepical and transseptal implantation of autologous CD 133+ bone marrow cells during bypass grafting improves cardiac function in patients with low ejection fraction. *J Card Surg* 35:740-746.
- Solazzo M, O'Brien FJ, Nicolosi V, Monaghan MG (2019) The rationale and emergence of electroconductive biomaterial scaffolds in cardiac tissue engineering. *APL Bioeng* 3:041501.
- Song C, Zhang X, Wang L, Wen F, Xu K, Xiong W, Li C, Li B, Wang Q, Xing MMQ, Qiu X (2019) An Injectable Conductive Three-Dimensional Elastic Network by Tangled Surgical-Suture Spring for Heart Repair. *ACS Nano* 13:14122-14137.
- Song X, Wang X, Zhang J, Shen S, Yin W, Ye G, Wang L, Hou H, Qiu X (2021) A tunable self-healing ionic hydrogel with microscopic homogeneous conductivity as a cardiac patch for myocardial infarction repair. *Biomaterials* 273:120811.
- Stamm C, Kleine HD, Choi YH, Dunkelmann S, Lauffs JA, Lorenzen B, David A, Liebold A, Nienaber C, Zurakowski D, Freund M, Steinhoff G (2007) Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. *J Thorac Cardiovasc Surg* 133:717-725.
- Steinhoff G et al. (2017) Cardiac Function Improvement and Bone Marrow Response -: Outcome Analysis of the Randomized PERFECT Phase III Clinical Trial of Intramyocardial CD133(+) Application After Myocardial Infarction. *EBioMedicine* 22:208-224.
- Su T, Huang K, Daniele MA, Hensley MT, Young AT, Tang J, Allen TA, Vandergriff AC, Erb PD, Ligler FS, Cheng K (2018) Cardiac Stem Cell Patch Integrated with Microengineered Blood Vessels Promotes Cardiomyocyte Proliferation and Neovascularization after Acute Myocardial Infarction. *ACS Appl Mater Interfaces* 10:33088-33096.
- Sugiura T, Hibino N, Breuer CK, Shinoka T (2016) Tissue-engineered cardiac patch seeded with human induced pluripotent stem cell derived cardiomyocytes promoted the regeneration of host cardiomyocytes in a rat model. *J Cardiothorac Surg* 11:163.
- Sun X, Wu J, Qiang B, Romagnuolo R, Gagliardi M, Keller G, Laflamme MA, Li RK, Nunes SS (2020) Transplanted microvessels improve pluripotent stem cell-derived cardiomyocyte engraftment and cardiac function after infarction in rats. *Sci Transl Med* 12.
- Suncion VY et al. (2014) Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial. *Circ Res* 114:1292-1301.
- Surder D, Manka R, Moccetti T, Lo Cicero V, Emmert MY, Klersy C, Soncin S, Turchetto L, Radrizzani M, Zuber M, Windecker S, Moschovitis A, Buhler I, Kozerke S, Erne P, Luscher TF, Corti R (2016) Effect of Bone Marrow-Derived Mononuclear Cell Treatment, Early or Late After Acute Myocardial Infarction: Twelve Months CMR and Long-Term Clinical Results. *Circ Res* 119:481-490.
- Takahashi M, Li TS, Suzuki R, Kobayashi T, Ito H, Ikeda Y, Matsuzaki M, Hamano K (2006) Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. *Am J Physiol Heart Circ Physiol* 291:H886-893.
- Tang J, Wang J, Huang K, Ye Y, Su T, Qiao L, Hensley MT, Caranasos TG, Zhang J, Gu Z, Cheng K (2018) Cardiac cell-integrated microneedle patch for treating myocardial infarction. *Sci Adv* 4:eaat9365.
- Traverse JH, Henry TD, Pepine CJ, Willerson JT, Chugh A, Yang PC, Zhao DXM, Ellis SG, Forder JR, Perin EC, Penn MS, Hatzopoulos AK, Chambers JC, Baran KW, Raveendran G, Gee AP, Taylor DA, Moye L, Ebert RF, Simari RD (2018) TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis. *Circ Res* 122:479-488.
- Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP (2003) Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. *Lancet* 361:47-49.
- Uemura R, Xu M, Ahmad N, Ashraf M (2006) Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. *Circ Res* 98:1414-1421.
- Ulmer BM, Stoehr A, Schulze ML, Patel S, Gucuk M, Mannhardt I, Funcke S, Murphy E, Eschenhagen T, Hansen A (2018) Contractile Work Contributes to Maturation of Energy Metabolism in hiPSC-Derived Cardiomyocytes. *Stem Cell Reports* 10:834-847.
- van Berlo JH, Molkentin JD (2014) An emerging consensus on cardiac regeneration. *Nat Med* 20:1386-1393.
- van der Spoel TI, Vrijsen KR, Koudstaal S, Sluijter JP, Nijssen JF, de Jong HW, Hoefler IE, Cramer MJ, Doevendans PA, van Belle E, Chamuleau SA (2012) Transendocardial cell injection is not superior to intracoronary infusion in a porcine model of ischaemic cardiomyopathy: a study on delivery efficiency. *J Cell Mol Med* 16:2768-2776.
- Walker BW, Lara RP, Yu CH, Sani ES, Kimball W, Joyce S, Annabi N (2019) Engineering a naturally-derived adhesive and conductive cardiopatch. *Biomaterials* 207:89-101.
- Wang WE, Yang D, Li L, Wang W, Peng Y, Chen C, Chen P, Xia X, Wang H, Jiang J, Liao Q, Li Y, Xie G, Huang H, Guo Y, Ye L, Duan DD, Chen X, Houser SR, Zeng C (2013) Prolyl hydroxylase domain protein 2 silencing enhances the survival and paracrine function of transplanted adipose-derived stem cells in infarcted myocardium. *Circ Res* 113:288-300.
- Wendel JS, Ye L, Zhang P, Tranquillo RT, Zhang JJ (2014) Functional consequences of a tissue-engineered myocardial patch for cardiac repair in a rat infarct model. *Tissue Eng Part A* 20:1325-1335.
- Wollert KC et al. (2017) Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. *Eur Heart J* 38:2936-2943.
- Wu SZ, Li YL, Huang W, Cai WF, Liang J, Paul C, Jiang L, Wu ZC, Xu M, Zhu P, Wang Y (2017) Paracrine effect of CXCR4-overexpressing mesenchymal stem cells on ischemic heart injury. *Cell Biochem Funct* 35:113-123.
- Xu JY et al. (2019) Transplantation efficacy of autologous bone marrow mesenchymal stem cells combined with atorvastatin for acute myocardial infarction (TEAM-AMI): rationale and design of a randomized, double-blind, placebo-controlled, multi-center, Phase II TEAM-AMI

- trial. *Regen Med* 14:1077-1087.
- Yamada Y, Wakao S, Kushida Y, Minatoguchi S, Mikami A, Higashi K, Baba S, Shigemoto T, Kuroda Y, Kanamori H, Amin M, Kawasaki M, Nishigaki K, Taoka M, Isobe T, Muramatsu C, Dezawa M, Minatoguchi S (2018) S1P-S1PR2 Axis Mediates Homing of Muse Cells Into Damaged Heart for Long-Lasting Tissue Repair and Functional Recovery After Acute Myocardial Infarction. *Circ Res* 122:1069-1083.
- Yan W, Guo Y, Tao L, Lau WB, Gan L, Yan Z, Guo R, Gao E, Wong GW, Koch WL, Wang Y, Ma XL (2017) C1q/Tumor Necrosis Factor-Related Protein-9 Regulates the Fate of Implanted Mesenchymal Stem Cells and Mobilizes Their Protective Effects Against Ischemic Heart Injury via Multiple Novel Signaling Pathways. *Circulation* 136:2162-2177.
- Yau TM et al. (2019) Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial. *JAMA* 321:1176-1186.
- Ye L, Zimmermann WH, Garry DJ, Zhang J (2013) Patching the heart: cardiac repair from within and outside. *Circ Res* 113:922-932.
- Ye L, Chang YH, Xiong Q, Zhang P, Zhang L, Somasundaram P, Lepley M, Swingen C, Su L, Wendel JS, Guo J, Jang A, Rosenbush D, Greder L, Dutton JR, Zhang J, Kamp TJ, Kaufman DS, Ge Y, Zhang J (2014) Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. *Cell Stem Cell* 15:750-761.
- Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. *N Engl J Med* 357:1121-1135.
- Yeung E, Fukunishi T, Bai Y, Bedja D, Pitaktong I, Mattson G, Jeyaram A, Lui C, Ong CS, Inoue T, Matsushita H, Abdollahi S, Jay SM, Hibino N (2019) Cardiac regeneration using human-induced pluripotent stem cell-derived biomaterial-free 3D-bioprinted cardiac patch in vivo. *J Tissue Eng Regen Med* 13:2031-2039.
- Yoshida S, Miyagawa S, Fukushima S, Kawamura T, Kashiyama N, Ohashi F, Toyofuku T, Toda K, Sawa Y (2018) Maturation of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes by Soluble Factors from Human Mesenchymal Stem Cells. *Mol Ther* 26:2681-2695.
- Yoshida S, Miyagawa S, Toyofuku T, Fukushima S, Kawamura T, Kawamura A, Kashiyama N, Nakamura Y, Toda K, Sawa Y (2020) Syngeneic Mesenchymal Stem Cells Reduce Immune Rejection After Induced Pluripotent Stem Cell-Derived Allogeneic Cardiomyocyte Transplantation. *Sci Rep* 10:4593.
- Zhang C, Hsieh MH, Wu SY, Li SH, Wu J, Liu SM, Wei HJ, Weisel RD, Sung HW, Li RK (2020) A self-doping conductive polymer hydrogel that can restore electrical impulse propagation at myocardial infarct to prevent cardiac arrhythmia and preserve ventricular function. *Biomaterials* 231:119672.
- Zhang J (2015) Engineered Tissue Patch for Cardiac Cell Therapy. *Curr Treat Options Cardiovasc Med* 17:399.
- Zhang J, Zhu W, Radisic M, Vunjak-Novakovic G (2018) Can We Engineer a Human Cardiac Patch for Therapy? *Circ Res* 123:244-265.
- Zhu D, Li Z, Huang K, Caranasos TG, Rossi JS, Cheng K (2021) Minimally invasive delivery of therapeutic agents by hydrogel injection into the pericardial cavity for cardiac repair. *Nat Commun* 12:1412.
- Zhu K et al. (2018) Lack of Remuscularization Following Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitor Cells in Infarcted Nonhuman Primates. *Circ Res* 122:958-969.
- Zuo S, Jones WK, Li H, He Z, Pasha Z, Yang Y, Wang Y, Fan GC, Ashraf M, Xu M (2012) Paracrine effect of Wnt11-overexpressing mesenchymal stem cells on ischemic injury. *Stem Cells Dev* 21:598-608.